Manufacturer of Controlled Substances; Notice of Registration, 7603 [2012-3268]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 29 / Monday, February 13, 2012 / Notices
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF JUSTICE
Sidney A. Rosenzweig, Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street SW.,
Washington, DC 20436, telephone (202)
708–2532. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
The
Commission instituted this investigation
on March 7, 2011, based on a complaint
filed by Graco Children’s Products Inc.
of Atlanta, Georgia (‘‘Graco’’). 76 FR
12368 (Mar. 7, 2011). The complaint
named as the sole proposed respondent
Baby Trend, Inc. of Ontario, California
(‘‘Baby Trend’’), and alleged a violation
of section 337 in the importation, sale
for importation, and sale within the
United States after importation of
certain strollers and playards by reason
of the infringement of certain claims of
U.S. Patent Nos. 6,669,225; 7,044,497;
7,188,858; 7,404,569; and 6,510,570.
On January 6, 2012, Graco and Baby
Trend jointly moved to terminate the
investigation in its entirety on the basis
of a settlement agreement. On January
18, 2012, the ALJ granted the motion as
an ID. Order No. 11 at 2–3.
No petitions for review of the ID were
filed. The Commission has determined
not to review the ID.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in
sections 210.21 and 210.42 of the
Commission’s Rules of Practice and
Procedure (19 CFR 210.21, 210.42).
erowe on DSK2VPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Issued: February 7, 2012.
By order of the Commission.
James R. Holbein,
Secretary to the Commission.
[FR Doc. 2012–3212 Filed 2–10–12; 8:45 am]
BILLING CODE 7020–02–P
VerDate Mar<15>2010
14:46 Feb 10, 2012
Jkt 226001
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated September 28, 2011,
and published in the Federal Register
on October 7, 2011, 76 FR 62450,
Noramco, Inc., 500 Swedes Landing
Road, Wilmington, Delaware 19801–
4417, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Morphine-N-oxide (9307) .............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Tapentadol (9780) ........................
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco, Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Noramco, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
7603
Dated: February 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–3268 Filed 2–10–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Notice of a Change in Status of an
Extended Benefit (EB) Period for
Alaska
Employment and Training
Administration, Labor.
ACTION: Notice.
AGENCY:
This notice announces a
change in benefit period eligibility
under the EB program for Alaska.
The following changes have occurred
since the publication of the last notice
regarding the State’s EB status:
• Alaska’s 13-week insured
unemployment rate (IUR) for the week
ending January 7, 2012 rose to meet the
6% threshold to trigger ‘‘on’’ to the EB
program. Alaska’s payable period in the
Extended Benefits program began
January 22, 2012.
The trigger notice covering state
eligibility for the EB program can be
found at: https://ows.doleta.gov/
unemploy/claims_arch.asp.
SUMMARY:
Information for Claimants
The duration of benefits payable in
the EB program, and the terms and
conditions on which they are payable,
are governed by the Federal-State
Extended Unemployment Compensation
Act of 1970, as amended, and the
operating instructions issued to the
states by the U.S. Department of Labor.
In the case of a state beginning an EB
period, the State Workforce Agency will
furnish a written notice of potential
entitlement to each individual who has
exhausted all rights to regular benefits
and is potentially eligible for EB (20
CFR 615.13(c)(1)).
Persons who believe they may be
entitled to EB, or who wish to inquire
about their rights under the program,
should contact their State Workforce
Agency.
FOR FURTHER INFORMATION CONTACT:
Scott Gibbons, U.S. Department of
Labor, Employment and Training
Administration, Office of
Unemployment Insurance, 200
Constitution Avenue NW., Frances
Perkins Bldg. Room S–4524,
Washington, DC 20210, telephone
E:\FR\FM\13FEN1.SGM
13FEN1
]]>Agencies
[Federal Register Volume 77, Number 29 (Monday, February 13, 2012)]
[Notices]
[Page 7603]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-3268]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated September 28, 2011, and published in the Federal
Register on October 7, 2011, 76 FR 62450, Noramco, Inc., 500 Swedes
Landing Road, Wilmington, Delaware 19801-4417, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053)..................... I
Dihydromorphine (9145)..................... I
Morphine-N-oxide (9307).................... I
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Phenylacetone (8501)....................... II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Morphine (9300)............................ II
Oripavine (9330)........................... II
Thebaine (9333)............................ II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Oxymorphone (9652)......................... II
Noroxymorphone (9668)...................... II
Tapentadol (9780).......................... II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Noramco, Inc. to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Noramco, Inc. to ensure that the company's registration is
consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and local laws, and
a review of the company's background and history. Therefore, pursuant
to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above
named company is granted registration as a bulk manufacturer of the
basic classes of controlled substances listed.
Dated: February 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-3268 Filed 2-10-12; 8:45 am]
BILLING CODE 4410-09-P
